Future Perspectives in Higher-Risk MDS
Dr Gustavo Rivero comments on novel treatment combinations and potential new biomarkers in patients with MDS.
SELECT-MDS-1: Review of Study Design and Objectives
Gustavo Rivero, MD, comments on the ongoing SELECT-MDS-1 trial and as well as reviewing the adverse events of the potential combination of tamibarotene with azacitidine in patients with higher-risk MDS.
A Potential Role for Tamibarotene in the Treatment of Higher-Risk MDS
Dr Gustavo Rivero reviews the treatment options for patients with newly diagnosed higher-risk MDS and discusses tamibarotene’s recent orphan drug designation.
RARA Gene Expression in Higher-Risk MDS
Dr Gustavo Rivero talks about the significance of the RARA gene in patients with higher-risk MDS.
Overview of Myelodysplastic Syndrome and the Importance of Biomarker Testing
An overview of myelodysplastic syndrome (MDS) and the role of biomarker testing in patients with the disorder.
Dr. Rivero on Monocytic Differentiation in AML
Gustavo Rivero, MD, discusses evolving therapies for patients with acute myeloid leukemia with monocytic differentiation.
Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies
Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
2 Commerce Drive Cranbury, NJ 08512